• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PolyPid Ltd.

    2/12/25 7:05:02 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    6-K 1 ea0230493-6k_polypid.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2025

     

    Commission file number: 001-38428

     

    PolyPid Ltd.

    (Translation of registrant’s name into English)

     

    18 Hasivim Street

    Petach Tikva 495376, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F          ☐ Form 40-F

     

     

     

     

     

     

    CONTENTS

     

    Appointment of New Director

     

    On February 12, 2025, PolyPid Ltd. (the “Company”) announced the appointment of Yitzchak Jacobovitz to its Board of Directors (the “Board”), effective February 10, 2025.

     

    Mr. Jacobovitz, age 49, currently is a partner at AIGH Capital Management, a position he has held since 2014. He has served as a director at the board of directors of Myomo, Inc. (NYSE American: MYO) since January 2023. Prior to his current positions, Mr. Jacobovitz was a managing director at Capstone, a policy research firm, and an analyst at Leap Tide Capital, a special situations hedge fund. Mr. Jacobovitz earned his Masters in Business Administration from Johns Hopkins University and is a Chartered Financial Analyst.

     

    The Board concluded that Mr. Jacobovitz is qualified to serve as a Director and is independent under the rules of the Nasdaq Stock Market. Mr. Jacobovitz has agreed not to receive compensation for his service as a Director. The Company expects to enter into its standard indemnification agreement with Mr. Jacobovitz, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. Mr. Jacobovitz is not a party to any transactions that are disclosable under Item 7.B of Form 20-F.

     

    Issuance of Press Release

     

    Attached hereto and incorporated herein is the Company’s press release issued on February 12, 2025, titled “PolyPid Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results.”

     

    The bullet points under the section titled “Recent Corporate Highlights,” the sections titled “Financial results for three months ended December 31, 2024”, “Financial results for the full year ended December 31, 2024”, “Balance Sheet Highlights,” and “Forward-looking Statements” and the financial statements in the press release are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658 and File No. 333-281863) and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703 and File No. 333-280662) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Exhibit No.    
    99.1   Press Release issued by PolyPid Ltd. on February 12, 2025, titled “PolyPid Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results.”

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      POLYPID LTD.
         
    Date: February 12, 2025 By: /s/ Dikla Czaczkes Akselbrad
        Name:  Dikla Czaczkes Akselbrad
        Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    SEC Filings

    View All

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    2/4/26 4:05:01 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PolyPid Ltd.

    SCHEDULE 13G/A - PolyPid Ltd. (0001611842) (Subject)

    1/30/26 1:02:52 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    12/31/25 4:01:17 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

    PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application ("NDA") meeting minutes from the U.S. Food and Drug Administration ("FDA") supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries. The FDA agreed that the Company's existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a rolling N

    12/3/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on PolyPid Ltd. with a new price target

    Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

    6/5/25 7:35:43 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

    H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

    6/2/25 8:53:56 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

    Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

    1/28/25 7:16:12 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    View All

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

    PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors (the "Board") since November 2023, will step down from the Board, effective as of August 17, 2025 as she assumes this new executive role. "We are delighted to welcome Dr. Tweezer-Zaks to the executive team at this pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results," said Dikla Czaczkes Aks

    8/12/25 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

    PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

    11/7/23 7:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    10/28/24 4:01:03 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Financials

    Live finance-specific insights

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 202

    11/12/25 7:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

    PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question o

    10/29/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care